Insulin Resistance Among Hepatitis C Infected Children

Ain Shams University

Status: Completed

Conditions: This Study is to Assess Occurence of Insulin Resistance Among Hepatits C Infected Children Whether Thalassemic or Survivors of Childhood Malignancy

Study type: Observational

Funder types: Other

Identifiers

NCT07238530

Pediatric Protocol (Other Identifier)

FMASU MSO 15/2025

Details and patient eligibility

About

The goal of this observational study was to study the occurrence of insulin resistance in hepatitis C virus infected children who were either thalassemic or survivors of childhood malignancy and its correlation to the HCV viral load and other metabolic factors.

The main question it aims to answer is:

1. Do children infected with Hepatitis C have a higher incidence of Insulin resistance compared to healthy controls of same age and gender?
2. Is Insulin resistance occurence affected by HCV viral load, blood transfusion frequency, or metabolic factors? Researchers will compare hepatitis c infected children who are either thalassemic or survivors of childhood malignant to healthy age and sex matched controls.

Participants will be subjected to:

• standardized Questionnaires,
• physical examination and
• laboratory investigations including liver functions (ALT, AST, Alkaline phosphatase), Prothrombin time, serum ferritin level, albumin, fasting glucose, fasting insulin level and Insulin resistance assessment by HOMA IR calculation.

Enrollment: 90 patients

Sex: All

Ages: 3 to 18 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• hepatitis C virus ribonucleic acid (RNA) positive children, who were following up at the pediatric hematology and oncology clinic

Exclusion criteria

• patients with concurrent active hepatitis B virus infection (positive for hepatitis B surface antigen) or
• autoimmune hepatitis,
• primary biliary cirrhosis (PBC),
• sclerosing cholangitis,
• haemochromatosis,
• α1-antitrypsin deficiency,
• Wilson's disease,
• patients with obesity (BMI > 25), or
• Type 2 DM.

Trial design

90 participants in 2 patient groups

Patient group included 60 hepatitis C infected children and adolescents

Description:

The patient group included 30 thalassemic patients and 30 malignancy survivors

Control group of 30 age and sex matched healthy children and adolescents